Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant (TECHNO)

Phase 2 Completed 230 enrolled GBG Forschungs GmbH AGO Study Group · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The present clinical trial will investigate the safety and efficacy of a sequential preoperative therapy with Epirubicin/Cyclophosphamide in combination with Paclitaxel/Trastuzumab, followed by postoperative Trastuzumab in patients with HER-2 overexpression primary breast cancer.

Timeline

Start: 2002-01
Primary completion: 2005-12
Completion: 2008-09

Publications

von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012 May 20;30(15):1796-804. doi: 10.1200/JCO.2011.38.8595. Epub 2012 Apr 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cyclophosphamide	Other / unclassified	600 mg/m2	Intravenous
Subject	Epirubicin	Small molecule	90 mg/m2	Intravenous
Subject	Paclitaxel	Small molecule	175 mg/m2	Intravenous
Subject	Trastuzumab	Monoclonal antibody	6 mg/kg	Intravenous

Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant (TECHNO)

Summary

Timeline

Publications

Drugs

Indications